Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women
Status:
Completed
Trial end date:
2004-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at the level of depo-medroxyprogesterone acetate (DMPA
or Depo-Provera) in the blood to see if is affected by certain anti-HIV drugs (nelfinavir
[NFV], efavirenz [EFV], indinavir [IDV] in combination with ritonavir [RTV], and nevirapine
[NVP]). This study will also look at the levels of these anti-HIV drugs to see if they are
affected by DMPA.
DMPA is a hormonal birth control method that is given as an injection. It is not known if
taking DMPA together with anti-HIV drugs changes the amount of DMPA and/or the amount of
anti-HIV drugs in the blood. If higher levels of DMPA occur, side effects may increase. If
lower levels of anti-HIV drugs occur, the drugs may become less effective against HIV. This
study will look at the levels of anti-HIV drugs and DMPA in the blood when these medications
are used together.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)